A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 17, Issue 3, 1998, Pages 235-238

  Haworth, Stephen J ^a   Christofalo, Barbara ^a   Anderson, Roger D ^b   Dunkle, Lisa M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Novum Pharmaceutical Research Services   (United States)

Author keywords

Cerebrospinal fluid; Stavudine

Indexed keywords

STAVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CEREBROSPINAL FLUID BARRIER; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0032032274     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199803010-00008     Document Type: Article

References (17)

1. Product information for Zerit (stavudine) capsules. In: Physician's desk reference. Montvale, NJ: Medical Economics, 1996:697-700.
2. Simpson DM, Tagliati M, Ramcharitar S. Neurological complications of AIDS: new concepts and treatments. Mt Sinai J Med 1994;61:484-91.
3. Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1-related neurological diseases: multicenter AIDS cohort study. 1985-1992. Neurology 1994;44:1892-900.
4. Cohen JA, Raps EC. Critical neurological illness in the immunocompromised patient. Neurol Clin 1995;13:659-77.
5. Conrad AJ, Schmid P, Syndulko K, Singer EJ, Nagra RM, Russell JJ, Tourtellotte WW. Quantifying HIV-1 RNA using the polymerase chain reaction on cerebrospinal fluid and serum of seropositive individuals with and without neurologic abnormalities. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:425-35.
6. Sotrel A, Multani P. Pathology of the nervous system in HIV-infected patients. In: Wormser GP, ed. AIDS and other manifestations of HIV infection. New York: Raven Press, 1992:543.
7. Price RW, Brew B, Sidtis J, Rosenblum M, Schleck AC, Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 1988;239:586-92.
8. Royal W III, Seines OA, Concha M, Nance-Sproson TE, McArthur JC. Cerebrospinal fluid human immunodeficiency virus type I (HIV-1) p24 antigen levels in HIV-1-related dementia. Ann Neurol 1994;36:32-9.
9. Singer EJ, Syndulko K, Fahy-Chandon BN, et al. Cerebrospinal fluid p24 antigen levels and intrathecal immunoglobulin G synthesis are associated with cognitive disease severity in HIV-1. AIDS 1994;8:197-204.
10. Janiszewski JS, Mulvana DE, Kaul S, Dandekar KA, Barbhaiya RH. High-performance liquid chromatographic determination of 2′,3′-didehydro-3′-deoxythymidine, a new anti-human immunodeficiency virus agent, in human plasma and urine. J Chromatogr 1992;577:151-6.
11. Farmen RH, Muniak JF, Pittman KA. Management of pharmacokinetic data using HP-3357/mainframe IBM interfacing. Drug Information J 1987;21:141-52.
12. Gibaldi M, Perrier D, eds. Pharmacokinetics, 2nd ed. New York: Marcel-Dekker, 1982:409-17.
13. Riegelman S, Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1980;8:509-34.
14. Dudley MN, Graham KK, Kaul S, Geletko S, Dunkle L, Browne M, Mayer K. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992;166:480-5.
15. Kim GP, Brett-Smith H, Friedland G, Chang CP, Griffith BP, Prusoff W, Cheng YC. Anti-HIV effect, toxicity, and pharmacokinetics of 2′,3′-didehydro-3′-deoxythymidine (d4T) at low/ moderate doses (abstract 561). In Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1992:204.
16. Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995;96:247-52.
17. Lin P-F, Samanta H, Rose RE, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994;170: 1157-64.